Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

Medpace (MEDP) closed the most recent trading day at $595.41, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.48% for the day. Elsewhere, the Dow saw a downswing of 0.29%, while the tech-heavy Nasdaq depreciated by 0.56%.

Shares of the provider of outsourced clinical development services have appreciated by 1.56% over the course of the past month, outperforming the Medical sector's loss of 2.01%, and the S&P 500's loss of 0.82%.

Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $708.75 million, reflecting a 7.4% rise from the equivalent quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.54 per share and a revenue of $2.84 billion, signifying shifts of +14.79% and +12.38%, respectively, from the last year.

Any recent changes to analyst estimates for Medpace should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace is holding a Zacks Rank of #2 (Buy) right now.

In terms of valuation, Medpace is currently trading at a Forward P/E ratio of 33.5. This signifies a premium in comparison to the average Forward P/E of 16.92 for its industry.

We can additionally observe that MEDP currently boasts a PEG ratio of 2.62. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.44.

The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research